Loading...
Ultragenyx Pharmaceutical Inc.
RARE•NASDAQ
Healthcare
Biotechnology
$29.90
$-11.54(-27.85%)
Ultragenyx Pharmaceutical Inc. (RARE) Financial Performance & Statements
Review Ultragenyx Pharmaceutical Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
29.01%
↑ 29.01%
Operating Income Growth
5.84%
↑ 5.84%
Net Income Growth
6.17%
↑ 6.17%
Operating Cash Flow Growth
12.77%
↑ 12.77%
Operating Margin
-86.94%
↓ 86.94%
Gross Margin
83.63%
↑ 83.63%
Net Profit Margin
-93.04%
↓ 93.04%
ROE
-186.49%
↓ 186.49%
ROIC
-50.34%
↓ 50.34%
Ultragenyx Pharmaceutical Inc. (RARE) Financial Statements
Explore quarterly and annual reports for Ultragenyx Pharmaceutical Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $164.88M | $139.49M | $147.03M | $108.83M |
| Cost of Revenue | $16.89M | $21.02M | $30.14M | $26.38M |
| Gross Profit | $147.98M | $118.47M | $116.88M | $82.45M |
| Gross Profit Ratio | $0.90 | $0.85 | $0.79 | $0.76 |
| R&D Expenses | $187.77M | $170.11M | $152.64M | $169.64M |
| SG&A Expenses | $82.50M | $80.35M | $80.60M | $78.16M |
| Operating Expenses | $270.26M | $250.46M | $233.25M | $247.80M |
| Total Costs & Expenses | $287.15M | $271.48M | $263.39M | $274.18M |
| Interest Income | $9.55M | $10.73M | $7.40M | $8.82M |
| Interest Expense | $15.52M | $15.71M | $15.96M | $15.85M |
| Depreciation & Amortization | $9.08M | $8.76M | $8.86M | $8.85M |
| EBITDA | -$108.80M | -$108.74M | -$105.92M | -$145.54M |
| EBITDA Ratio | -$0.66 | -$0.78 | -$0.72 | -$1.34 |
| Operating Income | -$122.28M | -$131.99M | -$116.36M | -$165.35M |
| Operating Income Ratio | -$0.74 | -$0.95 | -$0.79 | -$1.52 |
| Other Income/Expenses (Net) | -$11.13M | -$1.23M | -$14.38M | -$4.88M |
| Income Before Tax | -$133.40M | -$133.21M | -$130.74M | -$170.23M |
| Income Before Tax Ratio | -$0.81 | -$0.95 | -$0.89 | -$1.56 |
| Income Tax Expense | -$19000.00 | $303000.00 | $858000.00 | $455000.00 |
| Net Income | -$133.38M | -$133.52M | -$131.60M | -$170.68M |
| Net Income Ratio | -$0.81 | -$0.96 | -$0.90 | -$1.57 |
| EPS | -$1.47 | -$1.40 | -$1.52 | -$2.03 |
| Diluted EPS | -$1.47 | -$1.40 | -$1.52 | -$2.03 |
| Weighted Avg Shares Outstanding | $95.68M | $95.49M | $86.58M | $84.29M |
| Weighted Avg Shares Outstanding (Diluted) | $95.68M | $95.49M | $86.58M | $84.29M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan